BiotechTube
Adaptilens

Adaptilens

Irvine, United States· Est.
adaptilens.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4M

Overview

Adaptilens is pioneering a biomimetic approach to intraocular lenses (IOLs) for cataract surgery, seeking to address the significant limitations of current monofocal and premium IOLs. The company's lead product, the Adaptilens A-IOL, is designed to physically change shape in response to the eye's natural focusing mechanism, aiming to provide a full range of high-quality vision without common side effects like halos and glare. With a $17.5M Series A financing round announced, the company is advancing its technology through preclinical development. Its leadership combines clinical, scientific, and commercial expertise from the ophthalmology and medical device sectors.

Ophthalmology

Technology Platform

Proprietary biomimetic accommodating intraocular lens (A-IOL) made from a soft, flexible Bottle Brush Polymer (BBP). The lens is designed to physically change shape in response to the eye's ciliary muscle, mimicking the natural accommodation of a young crystalline lens to provide a full range of vision.

Funding History

1
Total raised:$4M
Seed$4M

Opportunities

The aging global population is driving a massive increase in cataract prevalence, with the U.S.
patient pool alone projected to double by 2050.
Current premium IOLs have significant drawbacks like halos and glare, creating a large unmet need for a lens that provides a full, high-quality range of vision without side effects.
A successful biomimetic accommodating IOL could capture a major share of the premium cataract surgery market and set a new standard of care.

Risk Factors

The technology must prove safe and effective in human clinical trials, a significant hurdle where previous accommodating IOL concepts have failed.
The device faces a lengthy and expensive FDA PMA regulatory pathway for a Class III device.
The company competes with well-funded industry giants (Alcon, J&J, Bausch + Lomb) and will need substantial additional capital to reach commercialization.

Competitive Landscape

The IOL market is dominated by large players like Alcon (AcrySof IQ PanOptix trifocal, Vivity EDOF), Johnson & Johnson Vision (TECNIS Symfony EDOF, multifocals), and Bausch + Lomb (Crystalens, a previous generation accommodating IOL). Adaptilens's key differentiator is its biomimetic, shape-changing mechanism aimed at avoiding the optical side effects inherent in multifocal/EDOF designs. It competes in the 'accommodating IOL' niche, which has seen limited clinical success to date.

More companies in Digital Health & Biotech SaaS →More companies in United States →